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Abstract
Background The desire for and use of nonsurgical
injectable esthetic facial treatments are increasing in Asia.
The structural and anatomical features specific to the Asian
face, and differences from Western populations in facial
aging, necessitate unique esthetic treatment strategies, but
published recommendations and clinical evidence for
injectable treatments in Asians are scarce.
Method The Asian Facial Aesthetics Expert Consensus
Group met to discuss current practices and consensus opin-
ions on the cosmetic use of botulinum toxin and hyaluronic
acid (HA) fillers, alone and in combination, for facial
applications in Southeastern and Eastern Asians. Consensus
opinions and statements on treatment aims and current
practice were developed following discussions regarding
pre-meeting and meeting survey outcomes, peer-reviewed
literature, and the experts’ clinical experience.
Results The indications and patterns of use of
injectable treatments vary among patients of different ages,
and among Asian countries. The combination use of botu-
linum toxin and fillers increases as patients age. Treatment
aims in Asians and current practice regarding the use of
botulinum toxin and HA fillers in the upper, middle, and
lower face of patients aged 18 to[55 years are presented.
Conclusions In younger Asian patients, addressing pro-
portion and structural features and deficiencies are important
to achieve desired esthetic outcomes. In older patients,
maintaining facial structure and volume and addressing lines
and folds are essential to reduce the appearance of aging. This
paper provides guidance on treatment strategies to address the
complex esthetic requirements in Asian patients of all ages.
Level of Evidence V This journal requires that the authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
Keywords Facial esthetics  Esthetic outcomes 
Treatment strategies  Hyaluronic acid fillers  Botulinum
toxin  Aging
Introduction
The advent of safe and predictable injectable agents,
expanded indications for their use, and improved under-
standing of their role in facial volumization, has helped
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practitioners advance from ‘two-dimensional’ treatment
strategies previously used to reduce facial lines in aging,
toward the use of injectable treatments aimed at creating
three-dimensionality to achieve facial esthetic restructuring
and rejuvenation in patients of all ages. These three-di-
mensional changes were previously only attainable through
surgery, but now can be achieved with botulinum toxin and
hyaluronic acid (HA) fillers in many situations.
In Asia, as in Western countries, botulinum toxin is used
extensively to treat dynamic lines in the upper face [1].
Botulinum toxin is also used to reshape and recontour the
face to correct perceived undesirable anatomical features
(e.g., reduce bulk of the masseter and activity of the
mentalis) in younger patients, and for rejuvenation in older
patients [1–9]. Intradermal injection of minute doses of
botulinum toxin into the full face and neck to achieve skin
rejuvenation [4, 9–11] has also gained popularity in some
parts of Asia.
HA fillers are used more commonly and extensively for
facial restructuring purposes in young Asians than in young
Western patients, to address structural features and deficien-
cies that are perceived as unesthetic [12]. Physicians com-
monly use HA to reshape and recontour facial features, to
address structural deficiency in the projection of the midline
facial features (medial malar, forehead, nose, chin, and gla-
bella), to correct ‘‘flatness’’ of the infraorbital and medial
malar regions, to reduce under-eye shadows, and to improve
projection and definition of the nose and chin, thereby creating
a visual illusion of ‘‘narrowing’’ to thewhole face (Fig. 1a) [9,
13–19]. More recently, physicians have used HA to volumize
and reshape the Asian forehead to create an esthetically
pleasing, convex, and youthful contour.
For older Asians, fillers are mainly used to restore vol-
ume loss in areas of the face that show signs of aging due to
volume deflation and tissue descent (such as the brow,
midface, periorbital, pre-auricular, and perioral regions),
and to address areas of intrinsic anatomical structural
deficiency that become more pronounced with age-related
volume loss, such as the medial malar, nose, inferior orbital
rim, jawline, pre- and post-jowl regions, perialar recess,
and chin (Fig. 1b).
Botulinum toxin and HA fillers are often used in combina-
tion to achieve the esthetic outcomesdesiredbyAsians (Fig. 1).
Combined treatment results in synergistic improvement com-
pared to individual use of these agents and is used as ‘‘age-
prevention’’ treatment in younger patients [20]. Although
numerous papers describing these techniques in Western pop-
ulations have been published [20–24], only one English-lan-
guage paper that describes combination injectable treatment in
Asians could be found in PubMed [25].
The physical features characteristic of the Asian face are
related to specific skeletal and morphological features that
differ from those of Caucasians [12]. Hence, different
treatment strategies are required to achieve esthetic or anti-
aging outcomes in Asians. To address the lack of adequate
recommendations and published clinical evidence available
to physicians who treat Asian patients for facial esthetic
concerns, the Asian Facial Aesthetics Expert Consensus
Group, comprising eight plastic surgeons, 11 dermatolo-
gists, an esthetic physician, and an anatomist from 11 Asia
Pacific countries (Table 1), met in Seoul on June 4–5, 2014
to discuss current local practices. The physicians had
7–30 years’ (mean 17 years) experience in facial esthetics
[12]. These experts were chosen based on their vast
experience of treating Asian patients, their presence on
advisory boards, the frequency of their presentations at
regional and international conferences, and their contribu-
tion to the literature. Described here are their consensus
opinions regarding the cosmetic facial use of botulinum
toxin and HA fillers in Asians from Southeast and Eastern
Asia, alone and in combination.
Methods of Consensus Development
To determine which noninvasive facial esthetic treatments
are most commonly used in Asian patients of different age
groups, the Expert Group members completed a pre-
meeting online survey and then during the meeting, they
were again surveyed to determine (i) the percentage of
patients that they treat for each individual indication, based
on the total number of patients who present to them for
noninvasive facial esthetic treatment, and (ii) the treatment
methods they use for each indication. The purpose of the
meeting survey was to give an indication of how common
each treatment concern is among their Asian patients, and
to provide an overview of common practice patterns.
Responses from the three Indian experts who attended were
not included in the data presented here because treatment
of patients from the Indian subcontinent is beyond the
scope of this publication. Rare procedures and high-risk
treatments requiring extensive experience were also not
discussed at the meeting or mentioned in this review.
A PubMed review of the English-language medical lit-
erature conducted with the search terms ‘‘hyaluronic acid
filler,’’ ‘‘botulinum,’’ ‘‘face,’’ ‘‘facial,’’ ‘‘Asia,’’ ‘‘Asian,’’
‘‘Korea,’’ ‘‘Korean,’’ ‘‘China,’’ ‘‘Chinese,’’ ‘‘Thailand,’’
‘‘Singapore,’’ ‘‘Indonesia,’’ ‘‘Japan,’’ and ‘‘Philippines’’
was completed before the meeting. Due to the paucity of
prospective, randomized, comparative, controlled studies
of botulinum toxin and HA fillers in Asian patients (with
only one English-language paper on their combination use
in Asians [25] being found), no formal process of evalu-
ating the published clinical evidence could be conducted.
The process used to develop the consensus statements
presented here has been described [12].
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This article does not contain any studies with human
participants or animals performed by any of the authors.
Results: Current Practice and Consensus Opinions
The following content reflects the proceedings of the Asian
Facial Aesthetics Expert Consensus Group meeting. The
consensus statements presented here were agreed by all the
Expert Group members.
Aims of Treatment in Asians
The aims of facial esthetic treatment in Asians are to
achieve clear, youthful, and fair skin; an oval facial shape
with smooth facial contours; large expressive eyes with
clearly defined palpebral creases; and an esthetically
pleasing, structural definition of the nose, chin, eyebrows,
and cheeks [12]. To achieve the ideal oval in Asian
patients, treatments to narrow and lengthen the lower face
may be required. This often involves reducing the bulk of
the masseter muscle mass with botulinum toxin, and the
use of HA fillers to project and lengthen the chin. Anterior
projection of the forehead, brows, and midface (medial
cheeks and nose) is a common goal, although the impor-
tance of this three-dimensional projection to the overall
esthetic outcome may be under-recognized by the patient.
As the average Asian face presents specific esthetic
challenges such as a square boxy face shape with lack of
Fig. 1 Effects of combination treatment in a younger and b older
Asian patients. a A 38-year-old Asian woman with a retruded
supraorbital rim, low radix and nasal dorsum, retruded medial malar,
recessed nasal spine, and hyperactive mentalis muscle, before
treatment (left panels). An esthetically improved facial appearance
(right panels) was achieved after dermal fillers were used to augment
the supraorbital rim, the nasal dorsum, nasal spine, columella, and the
medial cheek, and botulinum toxin and HA fillers were used to
improve chin projection and relax the hyperactive mentalis muscle as
follows: BOTOX (Allergan, Inc.), 16 U to mentalis; Juve´derm
VolumaTM (Allergan, Inc.), 1.5 ml to both medial cheeks, 1.2 ml to
the nose, 1.2 ml to the chin; Juve´derm Ultra Plus (Allergan, Inc.),
0.4 ml to supraorbital rim. (Photos courtesy of Dr. Steven Liew). b A
65-year-old Asian woman showing pan-facial aging, particularly
tissue deflation and volume loss in the temple and periocular region,
the perioral region, and the rest of the lower face, before treatment
(left panels). A significant improvement in appearance and youthful-
ness was achieved following combination therapy (right panels), in
which botulinum toxin was used in the upper face to reshape her
eyebrows; and HA filler was used to volumize and restructure the
temple, the tear trough, lateral cheek, nasolabial fold, perioral region,
jawline, and chin as follows: BOTOX, 24 U in the upper face, 6 U in
the mentalis, 30 U in the jawline and platysma; Juve´derm
VolumaTM, 1.2 ml in temples, 1 ml in both cheeks, 0.8 ml in pre-
auricular area, 1 ml in marionette lines and jowls; Juve´derm
VoliftTM (Allergan, Inc.), 1 ml in supraorbital rims, 1.6 ml in lips,
0.4 ml in nasolabial folds; Juve´derm VolbellaTM (Allergan, Inc.),
1 ml in both tear troughs (Photos courtesy of Dr. Peter Peng)
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vertical height, lack of anterior projection, a flat broad
nose, eyebags with prominent infraorbital hollows, retru-
sive maxilla and chin, deep nasolabial folds, and an obtuse
cervicomental angle, it is seldom possible to confine
treatment to a specific site. Augmenting the nose with an
HA filler automatically places emphasis on the adequacy of
chin projection, infraorbital volume, and malar projection,
all of which combine to give the face a more esthetic three-
dimensionality. At the same time, botulinum toxins may be
required to shape the eyebrows, relax mentalis strain, and
reduce the volume of hypertrophic masseter muscles,
which in turn narrows the width of the lower face and
triangulates it [8, 9].
Modern treatment plans thus require attention to surface,
volume, and movement in all facial areas. When treating
aging patients, the focus of treatment should involve the
whole face, rather than merely certain aspects, because
treatment of just one feature will affect the overall balance
and proportions of the face. To maintain balance and har-
mony, treatment of different areas of the face must be
addressed in a logical sequential fashion, and a global
approach can often provide optimal results [4].
It became apparent during this consensus meeting that
the significant change in esthetic.
Asian facial concepts and trends over the past four
decades have been the realization that Asian patients do not
want to look Western. Asian patients aspire to look more
beautiful or attractive within their own ethnic esthetic
boundaries. Some may desire a Pan-Asian (Eurasian) look,
but none wished to look ‘Western,’ in contrast to a com-
mon misperception held by many Western doctors. These
patients wish to look like good-looking Asians, rather than
good-looking Caucasians [8].
Consensus Statements on Aims of Treatment
in Asians
• The aims of esthetic facial treatment in Asians are
clear, youthful, fair skin and a smooth, oval facial shape
with adequately projected midline features.
• Increasing anterior projection of the midface/forehead
and vertical lengthening of facial height are key
components of achieving esthetic balance.
• Narrowing the lower face is the key to achieving the
ideal oval face shape.
• A full-face approach is required to achieve a balanced,
harmonious, more three-dimensional facial appearance.
• Full-face facial enhancement using botulinum toxin and
HA fillers is aimed at achieving maximal beauty while
maintaining the unique Asian appearance.
• Asian patients do not wish to look ‘Western.’
Table 1 Members of the Asian Facial Aesthetics Expert Consensus Group
Member Specialty Practice Years of experience in esthetic practice Country
Dr. Greg Goodman Dermatologist Private 30 Australia
Dr. Woffles Wu Plastic surgeon Private 25 Singapore
Dr. Hee Jin Kim Anatomist Public/university 23 Korea
Dr. Nantapat Supapannachart Dermatologist Public/university hospital 20 Thailand
Dr. Hideaki Sato Plastic surgeon Public/university hospital 20 Japan
Dr. Taro Kono Plastic surgeon Public/university hospital 20 Japan
Dr. Nobutaka Furuyama Plastic surgeon Private/university hospital 20 Japan
Dr. Henry Chan Dermatologist Private/university hospital 19 Hong Kong
Dr. Wilson Ho Plastic surgeon Private/university hospital 16 Hong Kong
Dr. Jonathan Yu Dermatologist Private 16 Philippines
Dr. Danru Wang Plastic surgeon Public/university hospital 16 China
Dr. Steven Liew Plastic surgeon Private 15 Australia
Dr. Hong Ki Lee Plastic surgeon Private 15 Korea
Dr. Hsien-Li Peter Peng Dermatologist Private 15 Taiwan
Dr. Yan Wu Dermatologist Public/university hospital 13 China
Dr. Rashmi Shetty Esthetic physician Private 13 India
Dr. Chytra Anand Dermatologist Private 13 India
Dr. Vandana Chatrath Dermatologist Private 12 India
Dr. Akiko Imaizumi Dermatologist Private 12 Japan
Dr. Marisa Pongprutthipan Dermatologist Public/university hospital 10 Thailand
Dr. Adri Prasetyo Dermatologist Private 7 Indonesia
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Current Practice for Nonsurgical Facial Esthetic
Treatment in Asians
The results of the surveys taken by the Expert Group are
presented in Tables 2, 3, 4, 5, 6, 7, and 8. The ranges of
values listed in Tables 3, 4, 5, 6, 7, and 8 include the
responses regarding Asian patients that were given by the
experts from China, Hong Kong, Indonesia, Japan, Korea,
the Philippines, Singapore, Taiwan, Thailand, and Aus-
tralia. When stating the range of botulinum toxin units they
used, the experts were asked to cite onabotulinum toxin A
(Botox; Allergan) units for the sake of uniformity and
consistency. To provide guidance regarding the most
common responses where practices differed (e.g., between
countries), smaller ranges that reflect the majority of the
participants’ responses are shown where applicable.
Most Common Treatments According to Patient
Age
The experts’ responses regarding the most commonly used
nonsurgical facial treatments in their Asian patients are
shown in Fig. 2 and Table 2. The survey revealed that
lasers/intense pulsed light are the most common treatments
used in Asian women younger than 40 years, most likely
because improvement of skin tone, color, texture, and
clarity is universally desirable. Skin treatments are not
described further because they are beyond the scope of this
manuscript. The survey also showed that the use of botu-
linum toxin and fillers, alone and in combination, is very
common in Asians (Fig. 2). Patterns of use vary among
patients of different ages, according to the changes that
result from facial aging and volume depletion, with com-
bination use of botulinum toxin and fillers increasing as
patients age. In young Asian patients wanting to increase
their attractiveness, treatment invariably involves increas-
ing the vertical height and anterior projection of the face
with fillers, and reducing lower facial width with botulinum
toxin. Older patients request facial rejuvenation procedures
to address age-related changes that are compounded by
anatomical structural deficiencies [12].
Treatment Areas, Indications, and Dosage
Upper Face
Being asked which are the most common types of dynamic
lines observed in the upper face of their Asian patients,
69 % (11/16) of the experts responded that it is the crow’s
feet indication that is most commonly treated, while 31 %
(5/16) mentioned glabella lines. The treatment used by
these experts to address upper facial lines is summarized in
Table 3.
Botulinum toxin doses used by this group of experts to
treat horizontal lines on the forehead are generally lower
than those used in Caucasians [26, 27] and in guidelines
published by the Korean Academy of Corrective Derma-
tology [1]. Suggested reasons were as follows: Asians
prefer a more natural-looking appearance (i.e., preservation
of facial expression) for the forehead and often have fewer
wrinkles in the upper face compared with age-matched
Caucasians [28]. There is less use of muscles in facial
expression and communication in the forehead area in
Asians, compared with Caucasians [29]. Finally, Asians
tend to have the appearance of ‘‘puffy’’ eyelids, and any
inadvertent eyebrow ptosis and heaviness of the brow will
exacerbate eyelid heaviness. Overtreatment and isolated
treatment of the frontalis (without co-treatment of the
glabella) is to be avoided. The dosage used in the forehead
varies according to the reason for treatment (e.g., to
Table 2 Summary of the most commonly used noninvasive esthetic treatments in Asian facial esthetics patients according to age
Priority Patient’s age
18–30 years 31–40 years 41–55 years [55 years
1 Laser/IPL Laser/IPL/botulinum toxin for
facial lines
Botulinum toxin for facial lines Combination of botulinum
toxin and HA fillers
2 Botulinum toxin for issues other
than facial linesa
Combination of botulinum
toxin and HA fillers
Combination of botulinum
toxin and HA fillers
HA fillers
3 Botulinum toxin for facial lines/
HA fillers
HA fillers HA fillers/laser/IPL Laser/IPL/botulinum toxin for
facial lines
Based on results of a pre-meeting survey of the Asian Facial Aesthetics Expert Consensus Group
This table shows that younger Asian patients are more concerned about the color and texture of their skin as evidenced by their prioritization of
lasers and IPL as their first choice of cosmetic treatments. In the 18–30-year age group, botulinum toxin was used mainly for reducing masseteric
bulk, while HA fillers were used mainly for correcting structural deficiencies such as a low nasal bridge or retrusive chin. In the above 55-year
age group, this sequence of priorities was reversed
HA hyaluronic acid, IPL intense pulsed light
a For example, masseter hypertrophy, mentalis hyperactivity
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address lines in the forehead, elevate the lateral brow, or
smoothen the forehead texture). The experts agreed that
this relatively lower dosage in the forehead and the
resulting shorter duration of effect are acceptable to their
patients. To ensure a more natural appearance, patients
accept that they must return for treatment more
frequently.
The general consensus regarding the number of glabella
injection points was at least five points, depending on the
clinical presentation at the time of injection. The majority
of experts (88 %) use 15–20 U onabotulinum toxin A in
total. This is similar to, or slightly lower than, consensus
recommendations of 5–30 U in Caucasian women [26, 27].
A lower dose in the glabella reduces the risk of splayed
eyebrows, avoids medial brow ptosis, achieves a more
natural-looking result, and preserves more normal move-
ment of the muscles. The number of injection points for
crow’s feet lines was not specified because of the wide
range of techniques and the wide range of botulinum toxin
dosage used.
The proportion of Asian patients who are treated for
volume deficit in the upper face, and the treatment types
used by these experts, is shown in Table 4. Volumization
and contouring of the upper third of the face in Asians has
been a well-established indication over the past 5 years
among the members of the Expert Group, in contrast to the
West, where facial volumization with HA fillers has only
more recently gained popularity [20].
Most Asians prefer a smooth forehead and glabella, and
full temples without hollows. In Korea, younger women are
Table 3 Current practice regarding injectable treatments to address upper face lines and folds in Asians
Glabella Forehead Crow’s feet
Dynamic lines





3–10 points to address frowning
(for the purpose of movement
only, not brow shaping) 88 %
use C5 injection points
5–12 U (depends on the
number of injection points
and the dose used at each
point, e.g., 1–4 U per
point)
6–12 U (depends on the
number of injection points
and the dose used at each
point, e.g., 1–4 U per
point)
Static lines
Percentage of Expert Group
using a combination of
botulinum toxin and HA
fillers, or botulinum toxin
only
Combination (100 %) 95 % use combination 5 %
use botulinum toxin only
Botulinum toxin only
(100 %)
Based on Expert Consensus Group Meeting survey outcomes
In the glabella region, 88 % of injectors use five or more injection points to reduce frowning as well as shape the brow. All injectors use a
combination of botulinum toxin and fillers here. In contrast, crow’s feet were only treated with botulinum toxin using a range of 6–12 U per side
HA hyaluronic acid
a Onabotulinum toxin A units were specified for the sake of uniformity
Table 4 Proportion of Asian patients treated for volume deficit in the upper face and volumizing treatment used










5–20 % (88 % responded
\5–10 %)
10–35 % (60 %
responded
20–30 %)
Percentage of Expert Group using a combination
of botulinum toxin and HA fillers, or HA fillers
only
88 % combination 100 % combination 81 % combination 100 % HA fillers
only
Based on Expert Consensus Group Meeting survey outcomes. Injection technique and dosage of fillers were not discussed because this depends
on the product used. Upper eyelids were not included because volumizing treatment of this area is uncommon
Volumization of the glabellar and forehead regions and the lateral and superior orbital rims was largely performed in combination with
botulinum toxins to decrease associated wrinkles, whereas in the temples these are treated with fillers only
HA hyaluronic acid
a Percentage of Expert Group members’ injectable facial esthetics patients
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more commonly treated to create a smooth, convex forehead
than those in other parts of Asia. Glabella volumization is
common in elderly East Asians (Chinese, Japanese, Kore-
ans). Age-related volume loss compounds the effect of a flat,
retruded frontal bone, which creates an obvious flattening of
the glabella that is considered undesirable by many Asian
women. Most experts agreed that there is a need for more
volumization and shaping of the upper face for many of the
Asian patients who request facial esthetic treatment. The
forehead, temple, and glabella are the most commonly
volumized areas. For volumization of the forehead and gla-
bella, botulinum toxin is used in combination with fillers to
minimize activity of the glabella and frontalis, and facilitate
the integration of the filler into the tissue. The Expert Group
highlighted that injecting the glabella is associated with a
risk of vascular complications and should remain the domain
of advanced practitioners.
Using fillers on the superior orbital rim improves the
forward projection of the supraorbital ridge and reduces the
appearance of ‘‘puffy’’ eyes. Although patients seldom
request this treatment, these experts recommend it to
achieve this outcome.
Consensus Statements on Upper Face Treatment
• In Asia, most patients prefer a natural look, with a
smooth forehead that retains the ability to show facial
expression.
• The relatively lower botulinum toxin dosages used in
the forehead, and the associated potential shorter
duration of effect, are acceptable to Asian patients.
• Upper face volumization is common among Asian
patients, to achieve optimal smoothness and anterior
projection of the forehead and upper face.
Table 5 Proportion of Asian patients treated for middle face lines or reshaping, and botulinum toxin dose used
Bunny lines Dynamic lines under eyelid Nasal shape Gummy smile
% patientsa Total doseb % patientsa Total
doseb































2–12 U, depending on
severity (69 % use 4 U or
a range that includes 4 U)
Based on Expert Consensus Group Meeting survey outcomes
Dynamic lines under the eyes and bunny lines were the most frequently treated areas in the midface, with dosages ranging from 4 to 6 U for both
sides. Treatment of the nose with onabotulinum toxin, either to reduce alar flare or raise the tip by decreasing the action of the depressor muscles,
was performed only by some experts
a Percentage of Expert Group members’ injectable facial esthetics patients
b Onabotulinum toxin A units were specified for the sake of uniformity
c To lift the tip or to address alar flare, several experts only treat either flare or tip, but not both
Table 6 Proportion of Asian patients treated for volume deficit in the middle third of the face
Age group Location/indication
Cheek complex Tear trough/
lower orbital
rim













0–20 % (75 %
responded
0–10 %)
0–15 % (75 %
responded
0–5 %)
0–50 % (75 %
responded
0–30 %)








































Based on Expert Consensus Group Meeting survey outcomes
The most frequently filled areas in the under 30-year age group were the nose, tear trough, and medial cheek areas. In the over 55-year age group,
the most frequently filled areas were the nasolabial fold, the medial cheek followed by the tear trough, and subzygomatic hollows
a Percentage of Expert Group members’ injectable facial esthetics patients
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• In general, younger women want a smooth forehead,
whereas older women want a smooth, contoured
forehead without temporal hollows.
Middle Face
The use of botulinum toxin to address dynamic lines in the
middle face, nasal shape, and gummy smile, and the propor-
tion of Asian esthetic patients treated for each indication, is
summarized in Table 5. Dynamic lines under the eye can
result frommuscle activity (facial expression) and/or volume
deficiency (inadequate structural support for skin and tissue).
The proportion of patients seeking treatment to address
infraorbital and bunny lines is relatively high in some coun-
tries, although Asians are less prone to photoaging (those
younger than 60 years generally have fewer facial wrinkles
than age-matched Caucasians [28, 30, 31]). Any lines that
become more noticeable are a concern for Asians. The pro-
portion of patients seeking treatment may also reflect a lower
tolerance of expression lines by Asians than Caucasians.
Table 7 Proportion of Asian patients treated for lines and folds of the lower face, and treatment used
Variable Location/indication














































20–100 U (81 %












Percentage of Expert Group using
combination treatment (C) or









100 % B 87 % B
13 % C
100 % B
Based on Expert Consensus Group Meeting survey outcomes
The mentalis and the platysma were the most frequently treated areas with botulinum toxin; the mentalis usually in combination with an HA
filler. Reduction of masseteric hypertrophy was the third most frequently treated area of the lower face with botulinum toxin, with a range of
40–80 U used for both sides
a Percentage of Expert Group members’ injectable facial esthetics patients
b Onabotulinum toxin A units were specified for the sake of uniformity





Percentage of patientsa 5–30 % (81 %
said 10–20 %)
10–50 % (ranges were
widely distributed)
10–60 % (88 %
said 20–40 %)
5–40 % (81 %
said 10–30 %)
HA fillers (F) only or combination (C) treatment





100 % C 75 % C
25 % F
Based on Expert Consensus Group Meeting survey outcomes
All experts responded that the chin was always treated with a combination of HA filler and botulinum toxin in order to achieve better chin
projection and elongation free of any signs of mentalis strain
HA hyaluronic acid
a Percentage of Expert Group members’ injectable facial esthetics patients
Aesth Plast Surg (2016) 40:202–214 209
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With its lack of dorsal height, poor tip support, and wide
nasal alar base, the Asian nose can often be treated with
HA fillers and botulinum toxin rather than surgery [25, 32].
Gummy smile can be caused by bony structural, dental, or
gingival factors, or muscle hyperactivity, all of which may
occur alone or in combination [33]. Bimaxillary protrusion
Fig. 2 Nonsurgical treatments
most commonly used by the
Expert Group for their Asian
facial esthetics patients,
according to patient age. Based
on results of a pre-meeting
survey of the Asian Facial
Aesthetics Expert Consensus
Group. HA hyaluronic acid, IPL
intense pulsed light
210 Aesth Plast Surg (2016) 40:202–214
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is a typical anatomical feature in Asians, which may also
explain the common need to treat gummy smile and to
relieve mentalis strain.
The proportion of Asian patients who are treated with
HA fillers for volume deficit in the midface is shown in
Table 5. Figure 3 shows the subregions treated for malar
volumization described in Table 6. In Asian patients, HA
fillers are most frequently used in the middle third of the
face. Infraorbital and mid-cheek volume loss are very
common and may occur as early as the second decade in
Asians, giving the impression of tiredness. The desire to
address the perceived undesirable facial features that
correlate with underlying characteristic anatomical struc-
tures [12] accounts for the relatively high proportion of
young patients seeking treatment to volumize the cheek
area and alar base, and to address nasal shape. It is
important to note that HA fillers are preferentially placed
in the medial cheek, and rarely in the lateral part, which
could cause widening of an already wide Asian midface.
This is in contrast to treatment of Caucasians, where HA
fillers are placed laterally to create cheekbones and widen
the face.
In Asians, the resulting increased anterior projection of
the medial cheek and other midline structures provides a
visual narrowing effect, which is a more desirable esthetic
outcome. The greater proportion of older patients who
receive volumization treatment (Table 6) reflects increasing
midface volume loss with aging, which is compounded by
the aforementioned structural deficiencies. The use of HA
fillers to treat nasolabial folds in Chinese and Korean
patients has been described elsewhere [13, 34]. Among these
experts, the common approach is first to address the midface,
with subsequent treatment directed at the nasolabial folds,
should it be necessary.
Consensus Statements on Midface Treatment
• Because Asians are less prone to photoaging [28, 30,
31], they generally have fewer wrinkles than age-
matched Caucasians. Hence, fine lines such as bunny
lines and dynamic lines under the eye become a
concern and lead to requests for treatment among
Asians.
• In younger Asian patients, the main treatment require-
ments are structural support for an underdeveloped
medial cheek, and optimization of nasal shape and chin
contour; the medial cheek is the most common area for
volumization.
• In older Asian patients, the main focus of treatment is
to restore volume of the midfacial areas associated with
age-related volume loss.
Lower Face
The proportion of Asian patients who receive injectable treat-
ment for lines and folds of the lower face, and the treat-
ments used, is shown in Table 7. Treatment for perioral
wrinkles is less common in Asia than in Western countries
[1]. The botulinum toxin dosage used by most of these
experts to address perioral lines and the depressor anguli is
similar to the dosing recommendations for Caucasians (4–6
and 2–15 U, respectively), but is lower for platysmal bands,
being 10–30 U by most experts (30–60 U are recom-
mended in Caucasians) [27]. A hyperactive mentalis
associated with retro- and microgenia is very common in
Asians, and treatment requires a similar dosage to the 4–10
U recommended for Caucasians [27].
The use of botulinum toxin to reduce masseter width is
well established in Asia as the most effective nonsurgical
shaping and facial slimming tool [1, 3, 5, 6, 35, 36]. Asian
women regard a square jaw as esthetically displeasing, and
masseter reduction treatment is common in patients aged
18–30 years. In older patients, due to age-related facial
volume loss and loss of skin elasticity, reducing the mas-
seter volume can lead to worsening facial appearance, with
hollowness and jowl formation. Therefore, treating their
masseters becomes less of a priority.
The use of intradermal botulinum toxin or Microbotox
[10, 11] is growing, as evidenced by the wide variation in
the proportions of patients given this treatment between
Asian countries where the treatment concept is still rela-
tively new (China, Philippines, Thailand) versus those in
which it has been used for many years (Singapore, Korea,
Japan, Taiwan). Microbotox is the injection of multiple
microdroplets of diluted onabotulinumtoxinA into the
dermis of the skin or the interface between the dermis and
the superficial layer of facial muscles that are attached to
its undersurface [10, 11]. A reduction of sweat and seba-




Fig. 3 Locations of midface malar volumization. 1 Lateral cheek; 2
medial cheek; 3 subzygomatic hollow
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skin, while the reduction of superficial facial muscle
activity leads to a marked reduction of surface wrinkling.
As the microdroplets are too small to diffuse into the
deeper muscle, muscle function is retained, which gives a
more natural, less frozen result. It is extremely useful in the
forehead, where horizontal rhytides can be reduced without
compromising eyebrow elevation and movement. It is also
used to treat the glabellar and crow’s feet regions, as well
as the lower face and neck (platysma). Less botulinum
toxin is used with the Microbotox technique than with
standard botulinum toxin injections. Typically, 20–28 U
(0.5–0.7 ml of a 100 U botulinum toxin vial diluted with
2.5 ml saline) is drawn into a 1-ml syringe and topped up
with 0.5–0.3 ml of 0.5 % lidocaine, to make a total volume
of 1 ml of solution. To treat the entire forehead, 7-point
glabellar and 8-point crow’s feet areas, and 1 ml of solu-
tion containing 20 U of botulinum toxin are sufficient. In
the lower face and neck, 1 ml of solution containing 28 U
is used per side (total of 56 U) to reduce superficial pla-
tysma activity and achieve better cervicomental and jaw-
line contouring. The results of a Microbotox treatment can
last for 3–4 months.
The proportion of Asian patients treated for volume or
structural deficits in the lower face, and the types of treat-
ments used, is shown in Table 8. In the Asian lower face,
HA fillers are most commonly used in the chin (vs. the lips
in Caucasians) [22]. Chin hypoplasia and mentalis hyper-
activity are best treated with a combination of botulinum
toxin and fillers [1]. Asians tend to have full lips; the top lip
may be thicker than the lower lip. The moderate proportion
of patients who request HA fillers in their lips do so, not to
increase their volume, but rather to create better shape and
esthetic balance. The Expert Group agreed that the ‘‘golden
ratio’’ Phi (1:1.618) [37] is not applicable to the size and
proportion of the upper and lower Asian lips. In Asians,
while lips where the lower lip is larger than the upper by
1:1.618 are considered beautiful, not all Asian patients
desire this relationship. Quite often Asians naturally have a
larger upper lip in proportion to the lower lip and this helps
offset an element of maxillary retrusion which is often seen
in the Asian face. As such, most Asian patients prefer to
have uniform enhancement of their lips and retain a rela-
tionship of upper to lower lip that may be the reverse of
what is considered ideal in the Caucasian face.
Consensus Statements for Lower Face Treatment
• A wide, square lower face is considered esthetically
undesirable among Asian women, as reflected in the
common request for treatment to reduce masseter
muscle bulk.
• Chin retrusion is a common feature of the Asian face,
which in turn leads to the high incidence of mentalis
strain and hyperactivity of the mentalis muscle. This is
reflected in the relatively high proportion of patients
who are treated in the chin area with a combination of
botulinum toxin and fillers.
Conclusions
The use of nonsurgical esthetic facial treatments is
increasing in Asia [38]. Surveys of current practice among
this Expert Group showed that the types of treatment
requested and provided correlate with anatomical structural
deficiencies observed in the Asian face, as well as age-
related changes, and they vary as patients age. Botulinum
toxin and HA fillers are often used in combination. To
achieve the desired esthetic outcome in younger Asian
patients, addressing proportion is key. In older patients,
maintaining facial structure and volume, in addition to
addressing lines and folds, is essential to reducing the
appearance of aging.
The desire for esthetic improvement, together with the
complexity of the structural deficits and aging processes in
the Asian face, often require a long-term management plan
that involves multiple treatment modalities. The often wide
variations in treatment practice and in the proportions of
patients treated for particular indications (Tables 2, 3, 4, 5,
6, 7) are a reflection of different patient demographics,
ethnicities, and ‘‘country-specific’’ popular desires; cultural
differences; and varying injecting practices in the region,
along with differences in perceptions of beauty that vary
even among experts. In addition to a thorough under-
standing of the characteristic anatomy and morphology of
the Asian face, a full-face approach and combination
treatment strategies involving energy-based devices, botu-
linum toxin, and HA fillers are often required to address the
complexity of many Asian patients’ esthetic concerns.
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Appendix
The Asian Facial Aesthetics Expert Consensus Group also
includes Drs. Danru Wang, China; Yan Wu, China; Rashmi
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References
1. Ahn BK, Kim YS, Kim HJ, Rho NK, Kim HS (2013) Consensus
recommendations on the aesthetic usage of botulinum toxin type
A in Asians. Dermatol Surg 39:1843–1860
2. Ahn J, Horn C, Blitzer A (2004) Botulinum toxin for masseter
reduction in Asian patients. Arch Facial Plast Surg 6:188–191
3. Wu WT (2010) Botox facial slimming/facial sculpting: the role of
botulinum toxin-A in the treatment of hypertrophic masseteric
muscle and parotid enlargement to narrow the lower facial width.
Facial Plast Surg Clin N Am 18:133–140
4. Wu WTL (2007) Non surgical facial rejuvenation with the 4R
principle: innovative uses of BOTOX and the Woffles lift. In:
Panfilov D (ed) Aesthetic surgery of the facial mosaic. Springer,
Berlin, pp 636–649
5. Yu CC, Chen PK, Chen YR (2007) Botulinum toxin A for lower
facial contouring: a prospective study. Aesthetic Plast Surg
31:445–451
6. Park MY, Ahn KY, Jung DS (2003) Botulinum toxin type A
treatment for contouring of the lower face. Dermatol Surg
29:477–483
7. Gaofeng L, Jun T, Bo P, Bosheng Z, Qian Z, Dongping L (2010)
Evaluation and selecting indications for the treatment of
improving facial morphology by masseteric injection of botuli-
num toxin type A. J Plast Reconstr Aesthet Surg 63:2026–2031
8. Wu WTL (2015) Botulinum toxin A injections for facial reju-
venation and reshaping. In: Chen YR, Li QF, Wu W, Park DH,
Takayanagi S, Wei FC (eds) Pu LLQ. Aesthetic plastic surgery in
Asians: principles and techniques, CRC Press, pp 149–169
9. Wu WTL (2011) Facial and lower limb contouring. In: Benedetto
AV (ed) Botulinum toxins in clinical aesthetic practice. 2nd edn.
Informa Healthcare pp 206–222
10. Wu WTL (2011) Skin resurfacing with Microbotox and the
treatment of keloids. In: Benedetto AV (ed) Botulinum toxins in
clinical aesthetic practice, 2nd edition. Informa Healthcare.
pp 190–205
11. Wu WTL (2015) Microbotox of the lower face and neck: evo-
lution of a personal technique and its clinical effects. Plast
Reconstr Surg 136(5 Suppl):92S–100S
12. Liew S, Wu WTL, Chan HH, Ho WWS, Kim HJ, Goodman GJ,
Peng PHL, Rogers JD (2015) Consensus on changing trends,
attitudes, and concepts of Asian beauty. Aesthetic Plast Surg. doi:
10.1007/s00266-015-0562-0
13. Ahn JY, Lee SH, Park KY, Hong CK, Song HJ, Park MY, Choi
YS, Seo SJ (2012) Clinical comparison of two hyaluronic acid-
derived fillers in the treatment of nasolabial folds: Mesoglow
and IAL System. Int J Dermatol 51:601–608
14. Bae JM, Lee DW (2013) Three-dimensional remodeling of young
Asian women’s faces using 20-mg/ml smooth, highly cohesive,
viscous hyaluronic acid fillers: a retrospective study of 320
patients. Dermatol Surg 39:1370–1375
15. Choi HS, Whipple KM, Oh SR, Priel A, Looi A, Korn BS,
Kikkawa DO (2011) Modifying the upper eyelid crease in Asian
patients with hyaluronic acid fillers. Plast Reconstr Surg
127:844–849
16. Lee SK (2011) Textbook of botulinum toxin and filler: better and
safer procedures for cosmetic surgeons. Hanmi Medical Pub-
lishing Co., Seoul
17. Lee SK, Kim HS (2014) Recent trend in the choice of fillers and
injection techniques in Asia: a questionnaire study based on
expert opinion. J Drugs Dermatol 13:24–31
18. Nanda S, Bansal S (2013) Upper face rejuvenation using botu-
linum toxin and hyaluronic acid fillers. Indian J Dermatol
Venereol Leprol 79:32–40
19. Vedamurthy M, Dermatology Task Force IADVL (2008) Stan-
dard guidelines for the use of dermal fillers. Indian J Dermatol
Venereol Leprol 74(Suppl):S23–S27
20. Raspaldo H, Gassia V, Niforos FR, Michaud T (2012) Global,
3-dimensional approach to natural rejuvenation: part 1—recom-
mendations for volume restoration and the periocular area.
J Cosmet Dermatol 11:279–289
21. Carruthers JD, Glogau RG, Blitzer A, Facial Aesthetics Consensus
Group F (2008) Advances in facial rejuvenation: botulinum toxin
type A, hyaluronic acid dermal fillers, and combination therapies—
consensus recommendations. Plast Reconstr Surg 121:5S–30S
22. Gassia V, Raspaldo H, Niforos FR, Michaud T (2013) Global
3-dimensional approach to natural rejuvenation: recommenda-
tions for perioral, nose, and ear rejuvenation. J Cosmet Dermatol
12:123–136
23. Sadick NS, Manhas-Bhutani S, Krueger N (2013) A novel
approach to structural facial volume replacement. Aesthet Plast
Surg 37:266–276
24. Yamauchi PS (2012) Soft tissue filler and botulinum toxin
treatment techniques. G Ital Dermatol Venereol 147:29–44
25. Wong GR, Chen WP (2011) Phosphatidylcholine/deoxycholate
lipolysis and hyaluronic acid augmentation to enhance nonsur-
gical lower facial contouring using botulinum toxin type A.
J Cosmet Dermatol 10:159–162
26. Raspaldo H, Baspeyras M, Bellity P, Dallara JM, Gassia V,
Niforos FR, Belhaouari L, Consensus G (2011) Upper- and mid-
face anti-aging treatment and prevention using onabotulinum-
toxin A: the 2010 multidisciplinary French consensus–part 1.
J Cosmet Dermatol 10:36–50
27. Carruthers A, Kane MA, Flynn TC, Huang P, Kim SD, Solish N,
Kaeuper G (2013) The convergence of medicine and neurotoxins:
Aesth Plast Surg (2016) 40:202–214 213
123
a focus on botulinum toxin type A and its application in aesthetic
medicine—a global, evidence-based botulinum toxin consensus
education initiative: part I: botulinum toxin in clinical and cos-
metic practice. Dermatol Surg 39:493–509
28. Nouveau-Richard S, Yang Z, Mac-Mary S, Li L, Bastien P, Tardy
I, Bouillon C, Humbert P, de Lacharriere O (2005) Skin ageing: a
comparison between Chinese and European populations. A pilot
study. J Dermatol Sci 40:187–193
29. Tzou CH, Giovanoli P, Ploner M, Frey M (2005) Are there ethnic
differences of facial movements between Europeans and Asians?
Br J Plast Surg 58:183–195
30. Chung JH (2003) Photoaging in Asians. Photodermatol Pho-
toimmunol Photomed 19:109–121
31. Tsukahara K, Fujimura T, Yoshida Y, Kitahara T, Hotta M,
Moriwaki S, Witt PS, Simion FA, Takema Y (2004) Comparison
of age-related changes in wrinkling and sagging of the skin in
Caucasian females and in Japanese females. J Cosmet Sci
55:351–371
32. Tanaka Y, Matsuo K, Yuzuriha S (2011) Westernization of the
asian nose by augmentation of the retropositioned anterior nasal
spine with an injectable filler. Eplasty 11:e7
33. Hwang HS, Park MK, Lee WJ, Cho JH, Kim BK, Wilkinson CM
(2012) Facial soft tissue thickness database for craniofacial
reconstruction in Korean adults. J Forensic Sci 57:1442–1447
34. Yan X, Xu J, Lu C, Ma Y, Li W (2009) A multicenter study of the
efficacy and safety of restylane in the treatment of nasolabial
folds in China. Plast Reconstr Surg 124:256e–257e
35. Choe SW, Cho WI, Lee CK, Seo SJ (2005) Effects of botulinum
toxin type A on contouring of the lower face. Dermatol Surg
31:502–507
36. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K (2003) Effects of
botulinum toxin type A on bilateral masseteric hypertrophy
evaluated with computed tomographic measurement. Dermatol
Surg 29:484–489
37. Swift A, Remington K (2011) BeautiPHIcation: a global
approach to facial beauty. Clin Plast Surg 38:347–377
38. GBI Research (2014) Facial aesthetics market to 2020. http://
www.researchmoz.us/facial-aesthetics-market-to-2020-economic-
recovery-drives-growth-in-the-us-as-increasing-awareness-fuels-
demand-in-developing-markets-report.html. Accessed 8 July 2014
214 Aesth Plast Surg (2016) 40:202–214
123
